Health Catalyst price target lowered to $2 from $3.75 at Stifel

Stifel lowered the firm’s price target on Health Catalyst (HCAT) to $2 from $3.75 and keeps a Hold rating on the shares. Q4 results were modestly better than pre-release, but Q1 revenue and EBITDA guidance was below consensus and FY26 guidance is delayed as the company conducts a strategic review, notes the analyst, who remains sidelined pending more “conclusive data points that the company is successfully executing its strategy.”